150 related articles for article (PubMed ID: 14739619)
1. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker.
Heath-Engel HM; Lingwood CA
Angiogenesis; 2003; 6(2):129-41. PubMed ID: 14739619
[TBL] [Abstract][Full Text] [Related]
2. Differential intracellular transport and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies.
Tam P; Mahfoud R; Nutikka A; Khine AA; Binnington B; Paroutis P; Lingwood C
J Cell Physiol; 2008 Sep; 216(3):750-63. PubMed ID: 18446787
[TBL] [Abstract][Full Text] [Related]
3. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice.
Ishitoya S; Kurazono H; Nishiyama H; Nakamura E; Kamoto T; Habuchi T; Terai A; Ogawa O; Yamamoto S
J Urol; 2004 Mar; 171(3):1309-13. PubMed ID: 14767339
[TBL] [Abstract][Full Text] [Related]
4. Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias.
Arab S; Russel E; Chapman WB; Rosen B; Lingwood CA
Oncol Res; 1997; 9(10):553-63. PubMed ID: 9507533
[TBL] [Abstract][Full Text] [Related]
5. Tumour plasticity and extravascular circulation in ECV304 human bladder carcinoma cells.
Fujimoto A; Onodera H; Mori A; Nagayama S; Yonenaga Y; Tachibana T
Anticancer Res; 2006; 26(1A):59-69. PubMed ID: 16475680
[TBL] [Abstract][Full Text] [Related]
6. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
7. Brefeldin A and filipin distinguish two globotriaosyl ceramide/verotoxin-1 intracellular trafficking pathways involved in Vero cell cytotoxicity.
Khine AA; Tam P; Nutikka A; Lingwood CA
Glycobiology; 2004 Aug; 14(8):701-12. PubMed ID: 15102715
[TBL] [Abstract][Full Text] [Related]
8. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
10. Localization of the binding site for modified Gb3 on verotoxin 1 using fluorescence analysis.
Picking WD; McCann JA; Nutikka A; Lingwood CA
Biochemistry; 1999 Jun; 38(22):7177-84. PubMed ID: 10353828
[TBL] [Abstract][Full Text] [Related]
11. Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy.
Beecken WD; Engl T; Jonas D; Blaheta RA
Int J Mol Med; 2009 Feb; 23(2):261-6. PubMed ID: 19148551
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
Kong D; Okamura M; Yoshimi H; Yamori T
Eur J Cancer; 2009 Mar; 45(5):857-65. PubMed ID: 19144509
[TBL] [Abstract][Full Text] [Related]
13. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice.
Arab S; Rutka J; Lingwood C
Oncol Res; 1999; 11(1):33-9. PubMed ID: 10451029
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
15. Different binding property of verotoxin-1 and verotoxin-2 against their glycolipid receptor, globotriaosylceramide.
Itoh K; Tezuka T; Inoue K; Tada H; Suzuki T
Tohoku J Exp Med; 2001 Dec; 195(4):237-43. PubMed ID: 11908825
[TBL] [Abstract][Full Text] [Related]
16. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.
He GA; Luo JX; Zhang TY; Hu ZS; Wang FY
Biochem Biophys Res Commun; 2004 May; 318(2):354-60. PubMed ID: 15120609
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
18. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
Scholz A; Wagner K; Welzel M; Remlinger F; Wiedenmann B; Siemeister G; Rosewicz S; Detjen KM
Gut; 2009 Feb; 58(2):261-70. PubMed ID: 18829975
[TBL] [Abstract][Full Text] [Related]
19. Escherichia coli verotoxin 1 mediates apoptosis in human HCT116 colon cancer cells by inducing overexpression of the GADD family of genes and S phase arrest.
Bhattacharjee RN; Park KS; Uematsu S; Okada K; Hoshino K; Takeda K; Takeuchi O; Akira S; Iida T; Honda T
FEBS Lett; 2005 Dec; 579(29):6604-10. PubMed ID: 16297916
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
